Circulating and Intracellular MiRNAs As Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 13

PMID 34638377

Citations 6

Authors

Chrystel Isca

Federico Piacentini

Ilenia Mastrolia

Valentina Masciale

Federica Caggia

Angela Toss

Claudia Piombino

Luca Moscetti

Monica Barbolini

Michela Maur

Massimo Dominici

Claudia Omarini

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNA) are small noncoding RNAs that can act as both oncogene and tumor suppressors. Deregulated miRNA expression has been detected in human cancers, including breast cancer (BC). Considering their important roles in tumorigenesis, miRNAs have been investigated as potential prognostic and diagnostic biomarkers. Neoadjuvant setting is an optimal model to investigate in vivo the mechanism of treatment resistance. In the management of human epidermal growth factor receptor-2 (HER2)-positive early BC, the anti-HER2-targeted therapies have drastically changed the survival outcomes. Despite this, growing drug resistance due to the pressure of therapy is relatively frequent. In the present review, we focused on the main miRNAs involved in HER2-positive BC tumorigenesis and discussed the recent evidence on their predictive and prognostic value.

Citing Articles

Predictive miRNAs Patterns in Blood of Breast Cancer Patients Demonstrating Resistance Towards Neoadjuvant Chemotherapy.

Fan J, Tang Y, Wang K, Yang S, Ma B Breast Cancer (Dove Med Press). 2023; 15:591-604.

PMID: 37593370 PMC: 10427486. DOI: 10.2147/BCTT.S415080.

Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis.

Tiberio P, Gaudio M, Belloni S, Pindilli S, Benvenuti C, Jacobs F Cancers (Basel). 2023; 15(13).

PMID: 37444533 PMC: 10340268. DOI: 10.3390/cancers15133424.

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.

Gianni C, Palleschi M, Merloni F, Bleve S, Casadei C, Sirico M Cancers (Basel). 2023; 15(1).

PMID: 36612091 PMC: 9817806. DOI: 10.3390/cancers15010096.

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs.

Gamez-Chiachio M, Sarrio D, Moreno-Bueno G Cancers (Basel). 2022; 14(18).

PMID: 36139701 PMC: 9496705. DOI: 10.3390/cancers14184543.

Prognosticating 2-Year Survival Rate of Breast Cancer Patients Through Plasma miRNA-21 and Other Associating Factors.

Zaky Romadhon P, Prayoga A, Bintoro S, Noor Diansyah M, Ayu Amrita P, Savitri M Int J Gen Med. 2022; 15:5557-5566.

PMID: 35712057 PMC: 9194493. DOI: 10.2147/IJGM.S361934.

References

Rezaei Z, Sebzari A, Kordi-Tamandani D, Dastjerdi K . Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance. DNA Cell Biol. 2019; 38(2):184-192. DOI: 10.1089/dna.2018.4427. View

Nakanishi H, Taccioli C, Palatini J, Fernandez-Cymering C, Cui R, Kim T . Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway. Oncogene. 2013; 33(6):702-12. PMC: 4294274. DOI: 10.1038/onc.2013.13. View

Modi S, Saura C, Yamashita T, Park Y, Kim S, Tamura K . Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2019; 382(7):610-621. PMC: 7458671. DOI: 10.1056/NEJMoa1914510. View

Tsukerman P, Yamin R, Seidel E, Khawaled S, Schmiedel D, Bar-Mag T . MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget. 2014; 5(23):12141-50. PMC: 4323010. DOI: 10.18632/oncotarget.2559. View

Jiang Q, He M, Ma M, Wu H, Yu Z, Guan S . MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep. 2015; 35(3):1425-32. DOI: 10.3892/or.2015.4502. View

Zhao Q, Liu Y, Wang T, Yang Y, Ni H, Liu H . MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Eur J Pharmacol. 2020; 884:173359. DOI: 10.1016/j.ejphar.2020.173359. View

Miao Y, Wang L, Zhang X, Xing R, Zhou W, Liu C . miR-30a inhibits breast cancer progression through the Wnt/β-catenin pathway. Int J Clin Exp Pathol. 2020; 12(1):241-250. PMC: 6944008. View

Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, Gonzalez-Alonso P . The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene. Sci Rep. 2017; 7:41309. PMC: 5264595. DOI: 10.1038/srep41309. View

Xiao Y, Humphries B, Yang C, Wang Z . MiR-205 Dysregulations in Breast Cancer: The Complexity and Opportunities. Noncoding RNA. 2019; 5(4). PMC: 6958506. DOI: 10.3390/ncrna5040053. View

10.

Cronin K, Harlan L, Dodd K, Abrams J, Ballard-Barbash R . Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010; 28(9):963-8. PMC: 5094051. DOI: 10.3109/07357907.2010.496759. View

11.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

12.

Quan Y, Huang X, Quan X . Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 2018; 16(5):6638-6642. PMC: 6202535. DOI: 10.3892/ol.2018.9440. View

13.

Li Z, Weng X, Xiong Q, Tu J, Xiao A, Qiu W . miR-34a expression in human breast cancer is associated with drug resistance. Oncotarget. 2018; 8(63):106270-106282. PMC: 5739732. DOI: 10.18632/oncotarget.22286. View

14.

Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K . MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun. 2013; 4:1393. PMC: 3723106. DOI: 10.1038/ncomms2393. View

15.

Nelson P, Baldwin D, Marie Scearce L, Oberholtzer J, Tobias J, Mourelatos Z . Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 2005; 1(2):155-61. DOI: 10.1038/nmeth717. View

16.

Zhao H, Kang X, Xia X, Wo L, Gu X, Hu Y . miR-145 suppresses breast cancer cell migration by targeting FSCN-1 and inhibiting epithelial-mesenchymal transition. Am J Transl Res. 2016; 8(7):3106-14. PMC: 4969447. View

17.

Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C . Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2006; 282(2):1479-86. DOI: 10.1074/jbc.M609383200. View

18.

Wang S, Lin R . MicroRNA and HER2-overexpressing cancer. Microrna. 2014; 2(2):137-47. PMC: 4120065. DOI: 10.2174/22115366113029990011. View

19.

Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

20.

Xia H, He T, Liu C, Cui Y, Song P, Jin X . MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem. 2009; 23(4-6):347-58. DOI: 10.1159/000218181. View